MedTrace Logo

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy

NCT00424138 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2018-10-11

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (\^18FDG) positron emission tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This clinical trial is studying \^18FDG PET/CT scans to see how well they predict response in patients undergoing chemotherapy for stage IIIB or stage IV non-small cell lung cancer.

Conditions

Interventions

RADIATION

FDG

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Wolfgang Weber, MD · Jonsson Comprehensive Cancer Center

  • Denise R. Aberle, MD · Jonsson Comprehensive Cancer Center

  • Barry A. Siegel, MD · Washington University Siteman Cancer Center

  • Anthony F. Shields, MD, PhD · Barbara Ann Karmanos Cancer Institute

  • Karen Rickard · City of Hope Comprehensive Cancer Center

  • Ramaswamy Govindan, MD · Washington University Siteman Cancer Center

  • Steven M. Dubinett, MD · Jonsson Comprehensive Cancer Center

  • Joel Karp, PhD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00424138 on ClinicalTrials.gov